175 related articles for article (PubMed ID: 23220403)
21. The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate.
Weisel JW; Litvinov RI
Cardiovasc Hematol Agents Med Chem; 2008 Jul; 6(3):161-80. PubMed ID: 18673231
[TBL] [Abstract][Full Text] [Related]
22. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
Wu JH; Diamond SL
J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
[TBL] [Abstract][Full Text] [Related]
23. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
[TBL] [Abstract][Full Text] [Related]
24. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis.
Wu JH; Siddiqui K; Diamond SL
Thromb Haemost; 1994 Jul; 72(1):105-12. PubMed ID: 7974357
[TBL] [Abstract][Full Text] [Related]
25. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
26. MASP-1 of the complement system alters fibrinolytic behaviour of blood clots.
Jenny L; Noser D; Larsen JB; Dobó J; Gál P; Pál G; Schroeder V
Mol Immunol; 2019 Oct; 114():1-9. PubMed ID: 31325724
[TBL] [Abstract][Full Text] [Related]
27. Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin.
Kovács A; Szabó L; Longstaff C; Tenekedjiev K; Machovich R; Kolev K
Thromb Res; 2014 Jan; 133(1):80-7. PubMed ID: 24094605
[TBL] [Abstract][Full Text] [Related]
28. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots.
Carr ME; Alving BM
Blood Coagul Fibrinolysis; 1995 Sep; 6(6):567-73. PubMed ID: 7578900
[TBL] [Abstract][Full Text] [Related]
29. Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix.
Sivaraman B; Sylvester A; Ramamurthi A
Mater Sci Eng C Mater Biol Appl; 2016 Feb; 59():145-156. PubMed ID: 26652359
[TBL] [Abstract][Full Text] [Related]
30. [PC-12 cells hydrolyze the fibrin clot by producing both plasminogen and its tissue activator].
Petrova IuI; Savchuk OM; Kalashnyk OM; Platonova TM; Skok MV; Cederholm-Williams S
Ukr Biokhim Zh (1999); 2004; 76(2):64-8. PubMed ID: 15915713
[TBL] [Abstract][Full Text] [Related]
31. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.
Zamolodchikov D; Strickland S
Blood; 2012 Apr; 119(14):3342-51. PubMed ID: 22238323
[TBL] [Abstract][Full Text] [Related]
32. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
[TBL] [Abstract][Full Text] [Related]
33. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
34. [Measurements of plasmin-alpha 2 plasmin inhibitor complex and FDP.D dimer levels in the fibrinolytic therapy of acute pulmonary thromboembolism].
Yamasawa F; Hasegawa N; Asano K; Sayama K; Fujita H; Urano T; Aoki T; Ishizaka A; Kanazawa M; Kawashiro T
Kokyu To Junkan; 1992 Jul; 40(7):685-90. PubMed ID: 1387724
[TBL] [Abstract][Full Text] [Related]
35. Antibody-directed fibrinolysis. An antibody specific for both fibrin and tissue plasminogen activator.
Bode C; Runge MS; Branscomb EE; Newell JB; Matsueda GR; Haber E
J Biol Chem; 1989 Jan; 264(2):944-8. PubMed ID: 2492021
[TBL] [Abstract][Full Text] [Related]
36. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
[TBL] [Abstract][Full Text] [Related]
37. Internal fibrinolysis of fibrin clots is driven by pore expansion.
Risman RA; Paynter B; Percoco V; Shroff M; Bannish BE; Tutwiler V
Sci Rep; 2024 Feb; 14(1):2623. PubMed ID: 38297113
[TBL] [Abstract][Full Text] [Related]
38. Increased plasma clot permeability and susceptibility to lysis are associated with heavy menstrual bleeding of unknown cause: a case-control study.
Szczepaniak P; Zabczyk M; Undas A
PLoS One; 2015; 10(4):e0125069. PubMed ID: 25909989
[TBL] [Abstract][Full Text] [Related]
39. Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins.
Gombás J; Tanka-Salamon A; Skopál J; Nagy Z; Machovich R; Kolev K
Blood Coagul Fibrinolysis; 2008 Jan; 19(1):82-8. PubMed ID: 18180621
[TBL] [Abstract][Full Text] [Related]
40. Clot lysis mediated by cultured human microvascular endothelial cells.
Speiser W; Anders E; Binder BR; Müller-Berghaus G
Thromb Haemost; 1988 Dec; 60(3):463-7. PubMed ID: 3149047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
